1. Home
  2. CGEM vs GHM Comparison

CGEM vs GHM Comparison

Compare CGEM & GHM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$17.55

Market Cap

904.7M

Sector

Health Care

ML Signal

HOLD

Logo Graham Corporation

GHM

Graham Corporation

HOLD

Current Price

$110.26

Market Cap

1.3B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
CGEM
GHM
Founded
2016
1936
Country
United States
United States
Employees
N/A
732
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
904.7M
1.3B
IPO Year
2020
1994

Fundamental Metrics

Financial Performance
Metric
CGEM
GHM
Price
$17.55
$110.26
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
3
Target Price
$30.13
$73.33
AVG Volume (30 Days)
1.3M
271.8K
Earning Date
05-11-2026
06-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
0.90
EPS
N/A
1.12
Revenue
N/A
$245,293,000.00
Revenue This Year
N/A
$14.54
Revenue Next Year
$5.20
$18.23
P/E Ratio
N/A
$96.35
Revenue Growth
N/A
16.86
52 Week Low
$5.68
$46.08
52 Week High
$17.40
$119.04

Technical Indicators

Market Signals
Indicator
CGEM
GHM
Relative Strength Index (RSI) 67.84 58.03
Support Level $11.87 $88.46
Resistance Level N/A N/A
Average True Range (ATR) 1.34 7.43
MACD 0.39 0.57
Stochastic Oscillator 93.97 72.23

Price Performance

Historical Comparison
CGEM
GHM

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

About GHM Graham Corporation

Graham Corp designs and manufactures mission-critical fluid, power, heat transfer, vacuum, and mixing technologies for the Defense, Energy & Process, and Space industries. In Defense, its equipment is used in nuclear and non-nuclear propulsion, power, fluid transfer, thermal management, and mixing systems. In Energy & Process industries, it supplies equipment for vacuum, heat transfer, mixing, and fluid transfer applications used in oil refining, chemical facilities, fertilizers, ethylene, methanol, energetics, food & beverage, medical, and alternative energy applications such as hydrogen and geothermal processes. In the Space industry, its equipment is used in propulsion, power, thermal management, mixing, and life support systems. It operates in the United States and other countries.

Share on Social Networks: